What Do High LDH Levels Indicate About Cancer?

Elevated lactate dehydrogenase (LDH) in the blood is one of the most consistent warning signs that a cancer is aggressive, fast-growing, or spreading. LDH is an enzyme found in nearly every cell in the body, and when cells are damaged or dividing rapidly, they release it into the bloodstream. In cancer specifically, high LDH reflects a tumor’s shifted metabolism and often predicts shorter survival, poorer response to treatment, and a higher chance the disease has metastasized. But LDH is not a cancer-specific marker, and understanding what it actually tells oncologists requires a closer look at how tumors hijack normal cell chemistry.

Why Cancer Cells Pump Out LDH

Healthy cells generate most of their energy using oxygen. Cancer cells, even when oxygen is available, tend to rely heavily on a faster but less efficient process that converts glucose into lactate. This metabolic quirk has been recognized for nearly a century and is sometimes called the Warburg effect. LDH, specifically the LDH-A form of the enzyme, is central to this process because it converts pyruvate into lactate and regenerates a molecule the cell needs to keep glycolysis running at high speed.¹ Cancer cells that divide quickly tend to overexpress LDH-A, and research across many tumor types confirms that this overexpression tracks with more aggressive disease.²

The practical result is straightforward: the bigger, faster-growing, or more widespread the tumor, the more LDH spills into the blood. A study of melanoma brain metastases found that serum LDH correlated with both the tumor’s proliferation rate and its volume.³ In breast cancer, LDH-A overexpression drives higher activity of the LDH5 isoenzyme compared to healthy tissue.⁴ So when your doctor sees high serum LDH in the context of cancer, the reading reflects real biological activity inside the tumor, not just a random lab fluctuation.

LDH as a Prognostic Marker Across Cancer Types

The strongest evidence linking elevated LDH to worse outcomes comes from melanoma, lymphoma, and lung cancer, though the pattern holds broadly. LDH has become such a reliable predictor that it is built into formal staging and prognostic systems for several cancers.

In metastatic melanoma, elevated LDH is recognized as both a predictive and prognostic factor for poor outcomes.⁵ A meta-analysis pooling data from melanoma patients receiving immunotherapy found that those with elevated pretreatment LDH had roughly two and a half times the risk of death compared to those with normal levels, and about 60 percent higher risk of their cancer progressing.⁶ In a study of patients treated with bevacizumab, every increase of 100 IU/L in baseline LDH was tied to a 44 percent increase in the risk of death.⁷ The American Joint Committee on Cancer actually incorporates LDH into its melanoma staging criteria, which is unusual for a simple blood test.

In diffuse large B-cell lymphoma, the most common aggressive form of non-Hodgkin lymphoma, LDH is one of five factors in the International Prognostic Index that doctors use to estimate how well a patient will do. One analysis found that among those five factors, an elevated LDH level was the single most relevant predictor of poor outcomes.⁸

Small cell lung cancer shows a similar pattern. In patients with limited-stage disease, those with normal LDH levels had a median survival of 18 months, while those with very high levels (above 300 U/L) survived a median of 12 months. The gap was even starker in extensive-stage disease, where high LDH levels cut median survival to about 7 months compared to 12 months for normal levels.⁹ In pediatric neuroblastoma, the ratio of LDH to albumin has been identified as an independent predictor of survival alongside tumor stage and genetic markers.¹⁰

Tracking Treatment Response in Real Time

Beyond establishing a baseline prognosis, LDH is valuable because it changes relatively quickly as a tumor responds to or escapes treatment. A simple blood draw can reveal whether things are heading in the right direction weeks before imaging can show the same thing.

This is particularly well-studied in metastatic melanoma patients receiving immunotherapy. In one cohort, patients who started with elevated LDH and then achieved a partial response to anti-PD-1 treatment saw their LDH drop by an average of about 27 percent. Those whose disease progressed, by contrast, saw an average increase of 39 percent. Patients whose LDH climbed more than 10 percent from an already elevated baseline had dramatically shorter survival, roughly 4 months compared to nearly 16 months for those whose levels held steady or fell.¹¹

In advanced non-small cell lung cancer, the pattern holds regardless of treatment type. Patients whose LDH remained elevated during treatment had between 1.3 and 2.8 times the risk of death at successive checkpoints through 24 weeks. Even among patients whose imaging showed the tumor was shrinking or stable, an elevated LDH at 6 weeks still predicted shorter survival.¹² That finding is worth pausing on, because it suggests LDH can sometimes reveal disease biology that a CT scan misses. A scan might show the tumor looking smaller, but if LDH is still rising, the underlying metabolic activity may not actually be under control.

In breast cancer, LDH levels are higher in patients at various stages of chemotherapy compared to healthy controls, and the trajectory of those levels over time can flag metastasis or recurrence before other signs appear.¹³ Across cancer types broadly, LDH measurement has become a standard supportive tool for monitoring treatment effects.¹⁴

How Lactate Helps Tumors Hide from the Immune System

The link between high LDH and poor immunotherapy response is not just a statistical quirk. There is a biological explanation. When tumor cells churn out lactate at high rates, they are not just fueling their own growth; they are actively reshaping the environment around the tumor in ways that suppress immune function.

The lactate that cancer cells export into the surrounding tissue creates an acidic microenvironment that makes it harder for immune cells to function. Cytotoxic T cells and natural killer cells, the frontline defenders that immunotherapy tries to activate, are directly impaired. At the same time, the excess lactate promotes immune-suppressive cell types including regulatory T cells and certain myeloid cells that further dampen anti-tumor responses.¹⁵ The net result is what researchers describe as an immunologically “cold” tumor, one that has essentially walled itself off from the body’s immune surveillance.¹⁶

This immune-suppressive effect also promotes resistance to chemotherapy, radiation, and targeted therapy, not only immunotherapy.¹⁶ And the lactate does more than just create an acid bath. It acts as a signaling molecule in its own right, feeding into neighboring cells and altering gene expression through chemical modifications to proteins.¹⁷ So high serum LDH is not merely a passive indicator that a tumor is large or fast-growing. It reflects a metabolic state that actively makes the cancer harder to treat.

The LDH-to-Albumin Ratio

Researchers have been exploring whether pairing LDH with other blood markers can sharpen its predictive power. The most promising combination is the LDH-to-albumin ratio, or LAR. Albumin is a protein made by the liver, and its levels tend to drop in patients who are malnourished or whose bodies are dealing with chronic inflammation, both common in advanced cancer. Combining a marker of tumor aggressiveness (LDH) with a marker of the body’s overall reserve (albumin) captures more prognostic information than either alone.

A large meta-analysis across multiple cancer types found that a high LAR roughly doubled the risk of death and nearly doubled the risk of disease recurrence.¹⁸ In neuroblastoma, LAR served as an independent predictor of survival in multivariate analysis, holding its own alongside established genetic and staging factors.¹⁰ The appeal of the LAR is practical: both LDH and albumin are cheap, widely available blood tests that can be run anywhere. No specialized equipment, no genetic sequencing, no imaging required.

Not Every Elevated LDH Means Cancer

If you see a high LDH result on a routine blood panel, the last thing you should do is assume cancer. LDH is present in virtually every tissue, and plenty of everyday conditions push it up. Heart attacks release LDH from damaged cardiac muscle. Liver disease, kidney injury, severe infections, hemolytic anemias (where red blood cells break down too fast), intense physical exercise, and even some medications can elevate it. A high LDH is a nonspecific signal that cells somewhere in the body are being damaged or are turning over rapidly.

Doctors rarely order LDH as a cancer screening test for this exact reason. Its value lies in monitoring and prognosis once a cancer is already diagnosed, or in raising suspicion alongside other abnormal findings. If your doctor orders LDH and your level comes back elevated, the context of the rest of your bloodwork, symptoms, and medical history determines what happens next.

There are also technical reasons for false elevations. One study documented that plasma samples transported through a hospital’s pneumatic tube system showed LDH levels 26 to 149 percent higher than hand-delivered samples, caused by mechanical disruption of white blood cells and platelets rather than actual hemolysis.¹⁹ Reference ranges can also vary between labs, so a result flagged as “high” at one facility might fall within normal range at another. This is worth knowing if you are comparing results from different clinics over time.

LDH in Diagnosing Malignant Pleural Effusions

One specialized use of LDH that cancer patients sometimes encounter involves fluid buildup around the lungs, called a pleural effusion. When fluid accumulates in the pleural space, doctors need to determine whether the cause is cancer, infection, or something else. LDH plays a role in this workup, but it is the ratio between serum LDH and another enzyme in the fluid that proves most useful.

A study examining patients with unexplained pleural effusions found that the ratio of serum LDH to pleural fluid adenosine deaminase (ADA) was highly accurate at distinguishing cancerous from non-cancerous causes. A ratio above 20 showed 98 percent sensitivity and 94 percent specificity for malignancy.²⁰ That kind of accuracy from simple lab values, without needing a biopsy, makes it a useful early sorting tool when a patient shows up with fluid around the lung and no clear diagnosis yet.

What Patients Should Know About Their LDH Results

If you are a cancer patient and your oncologist is tracking your LDH, a few things are worth understanding. First, the trend matters more than any single reading. An LDH level that is steadily climbing is more concerning than one that is elevated but stable. In melanoma patients on immunotherapy, the direction of LDH change within the first few weeks of treatment was one of the earliest signals of whether the treatment was working, appearing before imaging could show a difference.¹¹

Second, a high LDH does not automatically mean treatment will fail. It flags higher risk, and in some cases it may influence which treatment approach your doctor recommends, but patients with elevated LDH still respond to both immunotherapy and targeted therapy. The meta-analysis in melanoma showed worse odds, not zero odds. Patients with high LDH who do respond to treatment can see meaningful improvements in survival.

Third, LDH alone is never diagnostic. It is always interpreted alongside imaging, pathology, other blood markers, and the clinical picture. If your LDH is high but everything else looks reassuring, that is a very different situation from high LDH combined with rising tumor markers, new symptoms, and suspicious imaging findings.

LDH-A as a Potential Drug Target

Because LDH-A is so central to cancer cell metabolism and contributes to immune evasion, it has attracted interest as a therapeutic target. The logic is appealing: block the enzyme, and you might simultaneously slow tumor growth, reduce lactate production, make the tumor microenvironment less immunosuppressive, and sensitize the cancer to existing therapies. Research has demonstrated that LDH-A is aberrantly overexpressed across many cancer types and is associated with malignant progression.²

Several LDH-A inhibitors have shown promise in laboratory studies and animal models, but translating this into approved drugs has been slow. The challenge is selectivity. LDH exists in normal tissues too, and a drug that blocks it indiscriminately could cause serious side effects, particularly in the heart and skeletal muscles. Researchers are exploring small-molecule inhibitors, RNA-based approaches, and combination strategies that might lower tumor lactate production without crippling healthy cells. As of now, no LDH-A inhibitor is approved for clinical use, but the biological rationale is strong enough that early-phase clinical work continues.

A related therapeutic angle involves targeting the downstream effects of excess lactate. If drugs could prevent lactate from suppressing immune cells in the tumor environment, existing immunotherapies might work better in patients with high-LDH tumors. Some preclinical studies have explored combining lactate metabolism inhibitors with checkpoint inhibitors, aiming to convert immunologically “cold” tumors into “hot” ones that respond to immunotherapy.¹⁵ This remains experimental, but it represents one of the more biologically coherent strategies for overcoming the poor prognosis associated with high LDH.

1
OncoTargets and Therapy. Biochemical Origin of the Warburg Effect in Light of 15 Years of Research Experience: A Novel Evidence-Based View
2
PubMed Central. Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy
3
PubMed Central. Serum lactate dehydrogenase is associated with the presence and extent of preoperative peritumoral edema in melanoma brain metastases
4
PubMed Central. Lactate Dehydrogenase-A-Forming LDH5 Promotes Breast Cancer Progression
5
PubMed. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
6
PubMed Central. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis
7
PubMed Central. Metastatic Melanoma: Lactate Dehydrogenase Levels and CT Imaging Findings of Tumor Devascularization Allow Accurate Prediction of Survival in Patients Treated with Bevacizumab
8
PubMed. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab
9
Lung. Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – A retrospective single institution analysis
10
PubMed Central. Utilizing the Lactate Dehydrogenase-to-Albumin Ratio for Survival Prediction in Patients with Neuroblastoma
11
British Journal of Cancer. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
12
PubMed Central. Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer
13
Biomedicine & Pharmacotherapy / Biomedical and Pharmacology Journal. Lactate Dehydrogenase and Biochemical Markers as Indicators of Treatment Response in Breast Cancer
14
PubMed Central. The usefulness of lactate dehydrogenase measurements in current oncological practice
15
PubMed Central. Lactate signaling and immune suppression in tumors: mechanisms and therapeutic implications
16
Cancer Biomarkers. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments
17
PubMed Central. Lactate in the tumour microenvironment: From immune modulation to therapy
18
PubMed Central. Prognostic value of the lactate dehydrogenase to albumin ratio in cancer patients
19
PubMed. Falsely Increased Plasma Lactate Dehydrogenase without Hemolysis Following Transport through Pneumatic Tube System
20
PubMed Central. Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio)